APAC HbA1c Testing Market

Asia-Pacific HbA1c Testing Market Size (2024 to 2029)

The size of the Asia Pacific HbA1c Testing market is anticipated to grow at 12.67% CAGR from 2024 to 2029 and the regional market is anticipated to be worth USD 668.4 Mn by 2029 from USD 368.1 Mn in 2024.

One of the major factors likely to accelerate the growth of the HbA1c testing market in the Asia-Pacific region is the increase in diabetes research organizations and associations.

Furthermore, over the forecast period, an increase in crucial player initiatives and the prevalence of diabetes are likely to contribute to the market's growth. Furthermore, the rapid growth of medical tourism and increased demand for precise HbA1c level measurements are projected to propel the market forward. Moreover, the rise in the senior population and the influence of a sedentary lifestyle and an unhealthy diet are also predicted to fuel the expansion of the Asia Pacific HbA1c testing market.During the forecast period, the rapid growth in product approvals and launches and the incorporation of various technologies in HbA1c testing instruments are expected to provide substantial potential possibilities for the market. In addition, many companies in this region have implemented wellness programs that require employees to undergo routine medical testing to overall productivity and resource efficiency. These programs, in which an employee's diagnostic tests and, in some instances, some therapies are paid for, have significantly increased the testing volume of clinical laboratories, consequently raising market income.However, the restricted indications of HbA1c tests, high test costs and strict reimbursement policies are projected to limit the growth of the HbA1c testing market in the APAC region, while the rise in accuracy concerns among the population could pose a hurdle to the market's growth. In addition, hemoglobin A1c testing in the lab is expensive and time-consuming, which prevents patients from obtaining A1C testing.

This research report on the Asia-Pacific HbA1c testing market has been segmented and sub-segmented into the following categories.

Asia-Pacific HbA1c Testing Market - By Technology

• Ion-Exchange HPCL             
• Enzymatic Assay   
• Affinity Binding Chromatography  
• Turbidimetric Inhibition Immunoassay       
• Other       

Asia-Pacific HbA1c Testing Market - By Type

• Hand-Held Devices               
• Bench Top Devices   

Asia-Pacific HbA1c Testing Market - By End User

• Hospital    
• Home Care              
• Diagnostic laboratory          
• Research Institutions

Asia-Pacific HbA1c Testing Market - By Country

• India
• China
• Japan
• South Korea
• Australia
• New Zealand
• Thailand
• Malaysia
• Vietnam
• Philippines
• Indonesia
• Singapore
• Rest of APAC

Because of rapid expansion in healthcare facilities and rising per capita disposable incomes, Asia-Pacific is predicted to grow at a high growth rate during the forecast period. The market for HbA1c testing in the Asia Pacific is likely to see a quick increase in revenue creation as companies operating in the region place a greater emphasis on solid and strategic relationships. Local medical device companies invest in hemoglobin analyzers that provide quick and precise findings, which is seen as a potential growth driver for the APAC HbA1c testing market. The regional market is predicted to increase due to their increasing usage of modern diagnostic tools and technologies and strategic initiatives such as relationships and agreements by the key market players. Due to improved healthcare infrastructure and rising per capita disposable expenditures, Asia-Pacific is expected to be the fastest-growing market.

The Asia Pacific HbA1c testing market is expected to develop the fastest.

The predicted period's growth rate increases the number of diabetes laboratory tests and well-qualified healthcare workers such as diabetologists and clinicians due to the growing burden of diabetes. According to the International Diabetes Federation (IDF), by 2035, around 382 million people worldwide will have diabetes. Around 60% will live in Asia, with one-third in China. ARKRAY Factory Pinghu, Inc., primarily for the Chinese domestic market, conducted diabetes testing tools and in vitro diagnostic reagents in January 2020. Therefore, clinical items are projected to see greater demand in the rapidly growing Chinese market for medical products.

As of 2023, China is expected to show the most promising growth in this region. The Asia Pacific is projected to register the highest growth rate in the coming years owing to the growing cases of diabetes. Moreover, the low cost of healthcare in Asia counties is a key factor boosting medical tourism in the region, which in turn will aid the market growth

KEY MARKET PLAYERS

Companies playing an influential role in the APAC HbA1c Testing market are Tran Biomedicals ltd., Abbott Laboratories, Alere, Inc., Arkray, Inc., Bio-Rad Laboratories, Inc., Danaher Corporation, F. Hoffmann-La Roche Ltd., Siemens Healthcare and Trinity Biotech plc.